NTZ qualifies for orphan drug status.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D003457:Cryptosporidiosis / Q000188:drug therapy*; D006801:Humans; D009574:Nitro Compounds; D009965:Orphan Drug Production; D013844:Thiazoles / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000981:Antiprotozoal Agents; D009574:Nitro Compounds; D013844:Thiazoles; C041747:nitazoxanide